Definitive Contract HHSN261201300046C
Award Date 9/12/13
Potential Completion Date 6/30/14
Potential Value $299K
Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Ithaca, NY 14853, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
12
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
SBIR Program Phase I Action
Primary Consortia Member
Not listed Similar Awards
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Glycohub, Inc., a woman-owned small business. The contract is for the delivery of chemically defined glycosphingolipid head groups, with a total ceiling value of $298,447.00 and a completion date of December 30, 2014. As an SBIR Phase I contract, this represents the initial research and development effort to explore the feasibility of the proposed technology....
- <p>This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Omicron Biochemicals, Inc. The $999,991.00 fixed-price contract is for the "Synthesis of High-Mannose N-Glycans" and was awarded on September 18, 2015, with a completion date of September 17, 2017. The contract is a definitive contract, indicating it is a stand-alone award rather than under a larger contract vehicle.</p>
- This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Mediomics LLC, a woman-owned small business. The contract is for the development of glycosylation-specific research under SBIR Topic 294, with a ceiling value of $148,569. SBIR contracts are set-aside for small businesses to engage in research and development for the government. This Phase I contract represents the initial research and feasibility...
- <p>This is a Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a civilian agency, to Biotex, Inc. The contract is for the development of glycosylation-specific research, with a ceiling value of $149,919.00 and a completion date of October 14, 2012. The contract is a definitive contract with a firm fixed-price pricing type. This SBIR Phase I action is a set-aside for small businesses.</p>
- The U.S. National Cancer Institute awarded a $299,447 firm-fixed-price Small Business Innovation Research (SBIR) Phase I contract to Glycan Therapeutics Corporation, a small disadvantaged business, to conduct research on the chemoenzymatic synthesis of heparin sulfate oligosaccharides. Glycan Therapeutics specializes in developing methods for synthesizing and analyzing sulfated carbohydrates like heparan sulfate, which have potential therapeutic applications. This contract supports Glycan...
- <p>This is a $299,586 firm-fixed-price contract awarded by the National Cancer Institute, a civilian federal agency, to Omicron Biochemicals, Inc. for SBIR Phase I research on the synthesis of high-mannose N-glycans. The contract is set aside for small businesses and has an ultimate completion date of June 11, 2014. Omicron Biochemicals, Inc. is a for-profit manufacturer that has previously received federal contract and grant awards.</p>
- This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency, to Chemily LLC, a for-profit limited liability company. The contract has a ceiling value of $992,179.90 and is for the "CHEMO-ENZYMATIC SYNTHESIS OF STRUCTURALLY DEFINED COMPLEX-TYPE N-GLYCANS." The work is to be performed in Atlanta, GA. This SBIR Phase II contract builds upon prior Phase I research and is focused on developing chemo-enzymatic...
- This is a $1,646,541.00 Cost Plus Fixed Fee contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH) within the U.S. Department of Health and Human Services (HHS), to Glycan Therapeutics Corporation, a small disadvantaged business. The contract is for the chemoenzymatic synthesis of heparin sulfate under the Small Business Innovation Research (SBIR) Phase II program. The work is focused on developing synthetic heparan sulfate...
- This is a Phase II Small Business Innovation Research (SBIR) contract awarded by the National Cancer Institute (NCI), a civilian federal agency, to Siamab Therapeutics, Inc. The purpose of the contract is to develop technologies to characterize glycan moieties of glycoproteins in order to enhance the diagnostic capability of protein-based biomarkers. The specific goals include expanding the number of features for an existing sialic acid glycan array, optimizing the serum assay protocol,...
- This is a $600,000.00 Firm Fixed Price contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the U.S. Department of Health and Human Services, to Glycoscientific, L.L.C., a small business concern. The contract is for the development of reagents for immunologic analysis of non-mammalian and underrepresented mammalian models, under the Small Business Innovation Research (SBIR) program. The contract has a period of performance ending on November 23,...